Compare Stocks → Breaking News: Elon Musk Invents New Type of A.I. (Shocking) (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:EVAXNASDAQ:FRLNNASDAQ:LIANNASDAQ:OCUP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVAXEvaxion Biotech A/S$3.72-2.9%$3.68$2.82▼$18.50$20.13M-0.2213,279 shs6,759 shsFRLNFreeline Therapeutics$6.48$6.48$2.11▼$8.74$28.12M0.6612,055 shsN/ALIANLianBio$0.33+6.5%$0.68$0.27▼$4.99$35.18M0.231.04 million shs257,701 shsOCUPOcuphire Pharma$1.69-2.9%$1.85$1.50▼$4.71$43.68M0.39195,803 shs114,524 shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVAXEvaxion Biotech A/S-3.38%0.00%-9.49%-8.15%-77.45%FRLNFreeline Therapeutics0.00%0.00%0.00%0.00%+127.37%LIANLianBio0.00%-5.56%+1.07%-93.66%-87.99%OCUPOcuphire Pharma-2.88%-2.03%-3.16%-35.93%-64.53%My #1 investment for 2024 (Ad)It’s something you use every single day and don’t even know it.Click here to see my #1 investment for 2024.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEVAXEvaxion Biotech A/S2.3237 of 5 stars3.53.00.00.02.31.70.6FRLNFreeline TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ALIANLianBio1.0176 of 5 stars3.00.00.00.01.41.70.6OCUPOcuphire Pharma2.9256 of 5 stars3.64.00.00.01.51.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVAXEvaxion Biotech A/S3.00Buy$11.00195.70% UpsideFRLNFreeline Therapeutics2.00Hold$4.83-25.41% DownsideLIANLianBio2.00Hold$5.331,538.25% UpsideOCUPOcuphire Pharma3.20Buy$18.751,012.76% UpsideCurrent Analyst RatingsLatest FRLN, EVAX, LIAN, and OCUP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2024OCUPOcuphire PharmaCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2024OCUPOcuphire PharmaCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $18.005/13/2024OCUPOcuphire PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.004/3/2024EVAXEvaxion Biotech A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.004/2/2024EVAXEvaxion Biotech A/SLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$8.003/20/2024EVAXEvaxion Biotech A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.003/20/2024OCUPOcuphire PharmaAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$24.00 ➝ $20.00(Data available from 5/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVAXEvaxion Biotech A/S$70K287.50N/AN/A($1.17) per share-3.18FRLNFreeline TherapeuticsN/AN/AN/AN/A$12.07 per shareN/ALIANLianBioN/AN/AN/AN/A$2.71 per shareN/AOCUPOcuphire Pharma$19.05M2.29N/AN/A$1.78 per share0.95Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVAXEvaxion Biotech A/S-$22.12M-$6.76N/A28.62N/AN/A-451.63%-149.27%5/29/2024 (Estimated)FRLNFreeline Therapeutics-$88.97M-$5.59N/AN/AN/AN/A-150.46%-97.01%N/ALIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/AOCUPOcuphire Pharma-$9.99M-$0.49N/AN/AN/A-59.44%-24.57%-22.22%8/9/2024 (Estimated)Latest FRLN, EVAX, LIAN, and OCUP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023EVAXEvaxion Biotech A/SN/A-$0.16-$0.16-$0.16N/A$0.07 million3/8/2024Q4 2023OCUPOcuphire Pharma-$0.07-$0.21-$0.14-$0.21$3.47 million$1.69 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVAXEvaxion Biotech A/SN/AN/AN/AN/AN/AFRLNFreeline TherapeuticsN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/AOCUPOcuphire PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVAXEvaxion Biotech A/SN/A1.181.18FRLNFreeline TherapeuticsN/A1.95N/ALIANLianBioN/A10.0610.06OCUPOcuphire PharmaN/A8.9613.35OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVAXEvaxion Biotech A/S11.04%FRLNFreeline Therapeutics46.26%LIANLianBio74.85%OCUPOcuphire Pharma14.97%Insider OwnershipCompanyInsider OwnershipEVAXEvaxion Biotech A/S41.64%FRLNFreeline Therapeutics1.90%LIANLianBio7.59%OCUPOcuphire Pharma8.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEVAXEvaxion Biotech A/S495.41 million3.16 millionOptionableFRLNFreeline Therapeutics1524.34 million4.26 millionNot OptionableLIANLianBio163108.06 million99.86 millionNot OptionableOCUPOcuphire Pharma1425.92 million23.67 millionOptionableFRLN, EVAX, LIAN, and OCUP HeadlinesRecent News About These CompaniesMay 16 at 7:28 AM | americanbankingnews.comQ2 2024 Earnings Estimate for Ocuphire Pharma, Inc. Issued By HC Wainwright (NASDAQ:OCUP)May 16 at 3:44 AM | americanbankingnews.comOcuphire Pharma, Inc. (NASDAQ:OCUP) to Post FY2028 Earnings of $1.74 Per Share, HC Wainwright ForecastsMay 16 at 2:32 AM | americanbankingnews.comCanaccord Genuity Group Upgrades Ocuphire Pharma (NASDAQ:OCUP) to "Strong-Buy"May 15 at 4:56 AM | americanbankingnews.comCanaccord Genuity Group Cuts Ocuphire Pharma (NASDAQ:OCUP) Price Target to $18.00May 15 at 3:38 AM | americanbankingnews.comOcuphire Pharma (NASDAQ:OCUP) Rating Reiterated by HC WainwrightMay 13, 2024 | markets.businessinsider.comBuy Rating Affirmed: Ocuphire Pharma’s APX3330 Shows Promise for Diabetic Retinopathy and Pipeline ProgressMay 12, 2024 | finance.yahoo.comOcuphire Pharma First Quarter 2024 Earnings: Misses ExpectationsMay 10, 2024 | investorplace.comOCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q1 2024May 10, 2024 | globenewswire.comOcuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate UpdateMay 8, 2024 | americanbankingnews.comOcuphire Pharma (NASDAQ:OCUP) Shares Down 3.5% May 6, 2024 | globenewswire.comOcuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual MeetingMay 3, 2024 | globenewswire.comOcuphire Pharma to Present at the Aegis Virtual ConferenceApril 24, 2024 | finance.yahoo.comOcuphire Pharma, Inc. (OCUP)April 22, 2024 | globenewswire.comOcuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual MeetingApril 12, 2024 | ophthalmologytimes.comFirst patient enrolled in LYNX-2 Phase 3 studyApril 11, 2024 | globenewswire.comFirst Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive SurgeryApril 1, 2024 | thepharmaletter.comViatris launches Ryzumvi in USAApril 1, 2024 | markets.businessinsider.comOcuphire Announces Commercial Launch Of Ryzumvi In U.S. By Its Partner ViatrisApril 1, 2024 | globenewswire.comOcuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner ViatrisMarch 27, 2024 | investing.comOcuphire Pharma COO acquires $4.1k in company stockNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEvaxion Biotech A/SNASDAQ:EVAXEvaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.Freeline TherapeuticsNASDAQ:FRLNFreeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.LianBioNASDAQ:LIANLianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.Ocuphire PharmaNASDAQ:OCUPOcuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.